Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • NPI Medicare & Medicaid
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.28
    OpenPayerBilling CodesMiscellaneous Medical ServicesHCPCS hcpcs-m0240-casirivimab-imdevimab-infusion-injection-monitoring
    Ask Trek AI about this page

    HCPCS Level II M0240: Casirivimab and Imdevimab Infusion or Injection

    HCPCS Level II code M0240 describes administration of monoclonal antibody therapy — intravenous infusion or subcutaneous injection of casirivimab and imdevimab — and includes the infusion or injection procedure plus post-administration monitoring, with subsequent repeat doses as applicable; service type is therapeutic monoclonal antibody administration and the typical site of service is outpatient infusion clinic, ambulatory treatment center, or other outpatient settings for administration and observation.

    Customize your policy alerts

    Sign up for hcpcs M0240 policy alerts

    Get alerted when payer policies referencing M0240 are released or updated.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Table of contents

    Progress1 / 5

    Explore openpayer tools

    • Billing CodesCPT, HCPCS, DRG & more
    • Reimbursement RatesCommercial vs. Medicare rate reports
    • ProvidersHospitals & facilities
    • PayersPlans & market footprint
    • Taxonomy CodesNUCC specialty codes
    • ModifiersCPT modifiers & usage
    • Prior AuthorizationPA policies by payer & drug
    • Timely FilingFiling deadlines by payer
    • Coverage CriteriaMedical necessity by payer
    • Payer ContactsClaims, PA & appeals contacts
    View all tools

    Clinical & Coding Specifications

    Clinical Context

    A typical patient is an adult with confirmed mild-to-moderate SARS-CoV-2 infection who is at high risk for progression to severe COVID-19 (for example, older age, immunocompromise, chronic cardiopulmonary disease, diabetes, or obesity). The patient presents to an outpatient infusion center, emergency department, or clinic within the therapeutic window for monoclonal antibody therapy. After eligibility confirmation, informed consent, and baseline vital signs and allergy screening, the clinician orders M0240 for intravenous infusion or subcutaneous injection of casirivimab and imdevimab. The infusion team prepares the product under sterile technique, administers the medication per protocol, and monitors the patient during the infusion and for the post-administration observation period for infusion-related reactions or hypersensitivity. Documentation includes indication, start and stop times, dose and route, premedications if given, continuous monitoring notes, and discharge instructions. Repeat dosing may occur per clinical protocol and is documented as subsequent administrations using the same HCPCS procedure descriptor.

    Related CPT Codes

    CPT CodeDescriptionRelationship to This Procedure
    96413Chemotherapy administration, infusion technique; intravenous infusion, up to 1 hour, single or initial substance/drugUsed when a timed IV infusion and clinical documentation of infusion time align with chemotherapy/biologic administration conventions for billing time-based infusion services.
    96365Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hourCommonly used for initial therapeutic infusions in outpatient settings when payer prefers CPT reporting for infusion services accompanying monoclonal antibody administration.
    96366Intravenous infusion, each additional hour (List separately in addition to code for primary infusion)Used to report extended infusion time beyond the first hour when clinically required.
    99213Office or other outpatient visit for the evaluation and management of an established patient, typically 15 minutesOften billed for the pre-infusion evaluation or follow-up visit in clinic prior to or after M0240 administration.
    99024Postoperative follow-up visit, normally included in the global service, unrelated to anesthesiaMay be used for separate post-administration monitoring visits when payer rules permit separate billing.
    96372Therapeutic, prophylactic, or diagnostic injection (specify substance or drug)Used when the casirivimab and imdevimab are administered as injections (subcutaneous) and payer requires CPT-level injection reporting.

    Related Modifiers

    7 rows

    ModifierDescriptionWhen to Use
    22Modifier –22 (Increased Procedural Services) is used when a reported procedure is substantially more extensive than normally required. The CPT Manual and CMS state it may be appended only when the…- When to use: Append modifier -22 to a procedural CPT code when the service performed is substantially more extensive than the usual service described by that code — i.e., the procedure required…
    23Modifier -23 (Unusual Anesthesia) is used on anesthesia service CPT codes when a procedure that normally requires no anesthesia or only local anesthesia must be performed under general anesthesia…- Use modifier -23 only on anesthesia CPT codes (00100–01999) when a procedure that normally requires no anesthesia or only local anesthesia must be performed under general anesthesia because of…
    52Modifier ‑52 (Reduced Services) indicates that a service or procedure was partially reduced or omitted at the provider’s discretion, allowing reporting of the basic procedure number with a qualifier…- Use modifier -52 when a physician or qualified health professional electively reduces or omits part of a procedure or service (for example, performing fewer required views or omitting a portion of…
    53Modifier 53 (Discontinued Procedure) signals that a surgical or diagnostic service was begun by the physician but terminated because of extenuating circumstances that threatened the patient’s…- Use modifier -53 when a physician/qualified healthcare professional has started a surgical or diagnostic procedure (e.g., anesthesia administered, incision or scope insertion) and then discontinues…
    55Modifier –55 indicates the billing provider furnished only postoperative management for a procedure that has a global surgical period. According to AAPC, this modifier is appended to the same CPT…- Use modifier -55 when billing the same CPT surgical code that has a 10- or 90-day global period and you, as a provider other than the original surgeon, furnished ONLY postoperative management (no…
    56Modifier ‑56 indicates the reporting provider furnished only the preoperative management for a surgical procedure and did not perform the intraoperative or postoperative care. It is used in…- Use Modifier -56 when a provider performs only the preoperative management in a split‑care situation (one physician manages preop care while a different physician performs the intraoperative…
    62Modifier 62 indicates that two surgeons function as co‑surgeons, each performing distinct parts of the same primary surgical procedure. It is appended to the primary procedure code (and any…- Use modifier -62 when two surgeons act as co‑surgeons (both primary surgeons) on a single definitive primary procedure, each performing distinct parts of the same surgical procedure (append -62 to…

    Related Provider Taxonomies

    8 rows

    Taxonomy CodeSpecialtyNotes
    207Q00000XFamily Medicine PhysicianFamily Medicine is the medical specialty which is concerned with the total health care of the individual and the family. It is the specialty in breadt…
    208D00000XGeneral Practice PhysicianA physician who specializes in the general practice of diagnosing, treating, and managing patients with a variety of illnesses and conditions.
    363L00000XNurse Practitioner(1) A registered nurse provider with a graduate degree in nursing prepared for advanced practice involving independent and interdependent decision mak…
    3336C0002XClinic PharmacyA pharmacy in a clinic, emergency room or hospital (outpatient) that dispenses medications to patients for self-administration under the supervision o…
    246QL0901XDiplomate Laboratory Management Specialist/TechnologistTechnologists, Technicians & Other Technical Service Providers · Specialist/Technologist, Pathology
    207QA0505XAdult Medicine PhysicianThe NUCC recommends this code not be used. Choose a more appropriate code.
    174M00000XVeterinarianA doctor of veterinary medicine, trained and authorized to practice veterinarian medicine and surgery.
    225XR0403XDriving and Community Mobility Occupational TherapistOccupational therapists can optimize and prolong an older driver's ability to drive safely and ease the transition to other forms of transportation if…

    Related Codes

    HCPCS-M0075-CELLULAR-THERAPY-PROCESSING-PROVISION

    HCPCS Level II M0075: Cellular Therapy

    HCPCS-M0076-PROLOTHERAPY-INJECTION-THERAPY

    HCPCS Level II M0076: Prolotherapy

    HCPCS-M0100-INTRAGASTRIC-HYPOTHERMIA-GASTRIC-FREEZING

    HCPCS Level II M0100: Intragastric Hypothermia (Gastric Freezing)

    HCPCS-M0201-IN-HOME-VACCINE-ADMINISTRATION

    HCPCS Level II M0201: In-Home Vaccine Administration

    HCPCS-M0220-TIXAGEVIMAB-CILGAVIMAB-PRE-EXPOSURE-PROPHYLAXIS

    HCPCS Level II M0220: Tixagevimab and Cilgavimab Pre-Exposure Prophylaxis

    HCPCS-M0221-TIXAGEVIMAB-CILGAVIMAB-PRE-EXPOSURE-PROPHYLAXIS-HOME-ADMINISTRATION

    HCPCS M0221: Tixagevimab and Cilgavimab Pre-Exposure Prophylaxis

    HCPCS-M0222-BEBTELOVIMAB-INTRAVENOUS-INJECTION-MONITORING

    HCPCS Level II M0222: Bebtelovimab Intravenous Injection with Monitoring

    HCPCS-M0223-BEBTELOVIMAB-INTRAVENOUS-INJECTION-HOME-MONITORING

    HCPCS M0223: Intravenous Bebtelovimab with Home Monitoring

    HCPCS-M0224-PEMIVIBART-PRE-EXPOSURE-PROPHYLAXIS-INFUSION

    HCPCS M0224: Pemivibart Intravenous Infusion for Pre-Exposure Prophylaxis

    HCPCS-M0233-TOCILIZUMAB-INFUSION-COVID19-HOSPITALIZED-ADULTS

    HCPCS Level II M0233: Tocilizumab-aazg IV Infusion, First Dose

    Showing 1–10 of 27

    Frequently Asked Questions

    References

    1. 1.CPT® Codes and Descriptions. AAPC. Retrieved Aug 11, 2026.Maintains the CPT code set's official descriptions and guidelines, licensed from the American Medical Association, used as the definitional source for CPT codes on this page.
    2. 2.HCPCS Quarterly Update. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's quarterly release of HCPCS Level II codes and short/long descriptors, the source for HCPCS code definitions and update history.
    3. 3.ICD-10-CM Full Code List. Centers for Medicare & Medicaid Services (CMS). Retrieved Aug 11, 2026.CMS's complete ICD-10-CM diagnosis code list, used to cross-reference diagnosis codes associated with this procedure or service.
    Published by

    Trek Health powers OpenPayer with a leading commercial payer intelligence platform, seamlessly converting fragmented payer data into actionable insights for provider organizations.

    Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.